Role of genetic pattern on bone mineral density in thalassemic patients

Clinical Biochemistry

Volumn 43, Issue 10-11, 2010, Pages 805-807

  Gaudio, Agostino ^a   Morabito, Nancy ^b   Xourafa, Anastasia ^b   Currò, Monica ^b   Caccamo, Daniela ^b   Ferlazzo, Nadia ^b   Macrì, Ilaria ^b   La Rosa, Maria Angela ^b   Meo, Anna ^b   Ientile, Riccardo ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Alendronate 5kw; COLIA1; Osteoporosis; Thalassemia; VDR

Indexed keywords

ALENDRONIC ACID; CALCIUM; COLECALCIFEROL; COLLAGEN TYPE 1; COLLAGEN TYPE 1 ALPHA 1; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ADULT; ALLELE; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DNA POLYMORPHISM; DRUG RESPONSE; FEMALE; GENE FUNCTION; GENETIC ANALYSIS; GENOTYPE; HUMAN; MALE; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; THALASSEMIA MAJOR; TREATMENT DURATION; BETA-THALASSEMIA; GENETIC POLYMORPHISM; GENETICS;

ADULT; ALENDRONATE; BETA-THALASSEMIA; BONE DENSITY; FEMALE; HUMANS; MALE; POLYMORPHISM, GENETIC;

EID: 77953698837     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.04.070     Document Type: Article

References (10)

1. Voskaridou E., Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 2004, 127:127-139.
2. Ralston S.H. Genetic control of susceptibility to osteoporosis. J Clin Endocrinol Metab 2002, 87:2460-2466.
3. Morabito N., Lasco A., Gaudio A., Crisafulli A., Di Pietro C., Meo A., et al. Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int 2002, 13:644-649.
4. Ferrara M., Matarese S.M., Francese M., Borrelli B., Coppola A., Coppola L., et al. Effect of VDR polymorphisms on growth and bone mineral density in homozygous beta thalassaemia. Br J Haematol 2002, 117:436-440.
5. Mirandola S., Sangalli A., Mottes M. Rapid and efficient genotype analysis of the COL1a1 Sp1 binding site dimorphism, a genetic marker for bone mineral density. Mol Cell Probes 2002, 16:73-75.
6. Wonke B., Jensen C., Hanslip J.J., Prescott E., Lalloz M., Layton M., et al. Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major. J Pediatr Endocrinol Metab 1998, 11:795-801.
7. Origa R., Fiumana E., Gamberini M.R., Armari S., Mottes M., Sangalli A., et al. Osteoporosis in beta-thalassemia: clinical and genetic aspects. Ann N Y Acad Sci 2005, 1054:451-456.
8. Guzeloglu-Kayisli O., Cetin Z., Keser I., Ozturk Z., Tuncer T., Canatan D., et al. Relationship between SP1 polymorphism and osteoporosis in beta-thalassemia major patients. Pediatrics Int 2008, 50:474-476.
9. Dresner Pollack R., Rachmilewitz E., Blumenfeld A., Idelson M., Goldfarb A.W. Bone mineral metabolism in adults with beta-thalassaemia major and intermedia. Br J Haematol 2000, 111(3):902-907.
10. Perrotta S., Cappellini M.D., Bertoldo F., Servedio V., Iolascon G., D'Agruma L., et al. Osteoporosis in beta-thalassaemia major patients: analysis of the genetic background. Br J Haematol 2000, 111(2):461-466.